These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 21670699)

  • 41. Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    Meiser B; Price MA; Butow PN; Karatas J; Wilson J; Heiniger L; Baylock B; Charles M; McLachlan SA; Phillips KA
    Fam Cancer; 2013 Mar; 12(1):101-9. PubMed ID: 23203849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Schwartz ZP; Li AJ; Walsh CS; Rimel BJ; Alvarado MM; Lentz SE; Cass I
    Gynecol Oncol; 2023 Jun; 173():1-7. PubMed ID: 37030072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    Minig L; Cabrera S; Oliver R; Couso A; Rubio MJ; Iacoponi S; Martin-Salamanca MB; Carballo-Rastrilla S; Cádenas-Rebollo JM; García-Garcia A; Gil-Ibáñez B; Juan-Fita MJ; Patrono MG
    Clin Transl Oncol; 2018 Oct; 20(10):1337-1344. PubMed ID: 29623583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
    Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
    J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
    J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
    Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.
    Colgan TJ; Murphy J; Cole DE; Narod S; Rosen B
    Am J Surg Pathol; 2001 Oct; 25(10):1283-9. PubMed ID: 11688463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C; Lyon L; Conell C; Littell RD; Powell CB
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
    Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
    Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    Loizzi V; Cicinelli E; Del Vecchio V; Arezzo F; Deromemaj X; Kardhashi A; Paradiso A; Legge F; Natalicchio MI; Resta L; Resta N; Loconte DC; Cormio G
    Acta Biomed; 2022 Aug; 93(4):e2022051. PubMed ID: 36043985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    Blok F; Roes EM; van Leenders GJ; van Beekhuizen HJ
    BMC Cancer; 2016 Jan; 16():18. PubMed ID: 26768420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.
    Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW
    Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
    Hirst JE; Gard GB; McIllroy K; Nevell D; Field M
    Int J Gynecol Cancer; 2009 Jul; 19(5):826-9. PubMed ID: 19574767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
    Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
    Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    Van der Hoeven NMA; Van Wijk K; Bonfrer SE; Beltman JJ; Louwe LA; De Kroon CD; Van Asperen CJ; Gaarenstroom KN
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):463-471. PubMed ID: 29691126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
    Poon C; Hyde S; Grant P; Newman M; Ireland Jenkin K
    Int J Gynecol Cancer; 2016 Oct; 26(8):1415-20. PubMed ID: 27488216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.